the answers , page-29

Nice work lacky five.

Good news on NASDAQ listing. Would prefer proper ADR set up say 5 to 10 ratio for each ADR. They need to get cracking in order to beat the HRV trial announcement. Set up usgaap accounts and all the rest takes a few months. Hopefully they have already started.

HRV, LANI are the big drivers. Relenza could surprise next year and possible that we see some movement in the earlier stage pipe. Lots of cash to fund research but they have good ability to attract non dilutive funds.

For the record I think PC has performed well. Not his fault Aussie ivesrors don't understand the biotech market. From a research punting view they have done very well. Only one area of HCV failed. RSV is back as is HRV and the superbug has progressed.

May be slow for a few more months. But next year should hopefully surprise.